Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Geynisman on Sequencing of Agents for Kidney Cancer

Daniel M. Geynisman, MD
Published: Tuesday, Oct 03, 2017



Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Currently, tyrosine kinase inhibitors (TKIs) are given first, followed by drugs such as nivolumab (Opdivo), cabozantinib (Cabometyx), and lenvatinib (Lenvima) plus everolimus (Afinitor), states Geynisman.

Every patient is unique and has different needs and comorbidities. There are a number of options so determining treatment depends on the patient.
SELECTED
LANGUAGE


Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Currently, tyrosine kinase inhibitors (TKIs) are given first, followed by drugs such as nivolumab (Opdivo), cabozantinib (Cabometyx), and lenvatinib (Lenvima) plus everolimus (Afinitor), states Geynisman.

Every patient is unique and has different needs and comorbidities. There are a number of options so determining treatment depends on the patient.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x